Search

Background: In recent years, policymakers have paid particular attention to the emergence of a robust for-profit hospice sector and increased hospice use by nursing home residents. Previous research has explored financial incentives for nursing home-hospice use, but there has been limited research on nursing home-hospice partnerships and none on the extent of nursing home-hospice common ownership., Objective: To describe trends in nursing home-hospice contracting and common ownership and to identify potential tradeoffs in care provided by nursing homes and hospice agencies that share common ownership., Research Design: Retrospective cohort study of nursing home-hospice patients between 2005 and 2015., Results: Between 2005 and 2015, the number of hospice agencies and nursing homes with common ownership grew substantially, now representing almost 1-in-5 providers in each sector. Relative to individuals using hospice in nursing homes without common ownership, adjusted analyses found that individuals receiving hospice from a commonly owned agency had a greater likelihood of having stays of 90 days or more [odds ratio (OR)=1.06; 95% confidence interval (CI), 1.02-1.10], having a stay resulting in a live discharge (OR=1.06; 95% CI, 1.02-1.11), and having at least 1 registered nurse/licensed practical nurse visit during the last 3 days of life (OR=1.17; 95% CI, 1.05-1.29); these individuals also had a lower mean visit hours per day (-0.07; P=0.003)., Conclusions: Common ownership between hospice agencies and nursing homes is an emerging trend that reflects a broader push toward consolidation in the health care sector. Our analyses highlight potential concerns relevant to Medicare payment policy and are a first step toward improving our understanding of these trends and their implications.

Objective: Expanded health risk appraisal (HRA) surveys can help employers target chronic conditions for outreach or disease management interventions by providing data on the prevalences of conditions and their effects on work performance. However, concerns exist about the accuracy of this data because most HRAs have low response rates. We evaluated these concerns by examining the prevalences and work impairments associated with chronic conditions across four HRA subsamples that differed in intensity of recruitment effort., Methods: Two thousand five hundred thirty-nine working people were invited to complete an expanded HRA survey that included questions about chronic conditions, work impairments, and demographics. Condition prevalences and associations between conditions and work impairment were compared across subsamples who responded after a single mailing, after two mailings, and in a telephone interview after the mailings either with or without a 20 dollars incentive., Results: Consistent with previous research, response rates varied dramatically across the four subsamples (from 20.1% with only one mailing to 67.7% with telephone administration and a financial incentive). However, the estimated prevalences of chronic conditions, levels of work impairment, and effects of chronic conditions on work impairment did not differ with intensity of recruitment effort., Conclusions: Expanded HRAs can provide useful data on the prevalences and work impairments associated with chronic conditions even if response rates are low. Confirmation of these results is required, however, in new samples. Additional research is also needed on innovative and cost-effective strategies to improve HRA response rates.

Administration of selective serotonin reuptake inhibitors (SSRIs) may increase plasma concentrations of concomitant medications that are also metabolized by the cytochrome P-450 system (CYP-450), in particular by the 2D6 and 3A4 isoenzymes. This may lead to side effects or other clinical events that might be expected to incur higher health-care expenditures. The purpose of this study was to assess whether there was a difference in expenditures during the first 90 days of SSRI therapy with paroxetine or sertraline versus fluoxetine in patients who were also receiving a stable dosage of a nonpsychiatric drug also metabolized by the CYP-450 2D6 or 3A4 isoenzyme systems. A sample of 2445 patients who initiated therapy with an SSRI while receiving a stable dosage of a nonpsychiatric drug was obtained from a private insurance claims database. Multivariate regression techniques were used to estimate total health-care expenditures in the first 90 days after receiving a prescription for an SSRI. After adjusting for nonrandom SSRI prescription patterns and controlling for observable and unobservable characteristics that might correlate with SSRI selection, total health-care expenditures were 95% higher for patients initiating SSRI therapy with sertraline or paroxetine compared with fluoxetine. Results suggest that there are cost differences between SSRIs during concomitant therapy with drugs also metabolized by the CYP-450 system. To determine whether there are additional differences in expenditures across SSRIs, future research should focus on (1) simultaneous initiation of SSRI therapy and a nonpsychiatric drug also metabolized by the CYP-450 enzyme system, and (2) addition of nonpsychiatric drug therapy to stable SSRI therapy. Relationships between additional expenditures, drug interactions, and clinical outcomes should also be assessed directly using medical records and patient interview data that are not available in claims-based files.